Navigation Links
Shire plc: Strong Third Quarter and Increased Non GAAP Earnings Expectations
Date:10/24/2013

>1].

Our core effective tax rate on Non GAAP income is anticipated to remain in the range of 18-20%.

Taken together, we are increasing our guidance to reflect our expectation of delivering mid-to-high teens Non GAAP earnings growth for the full year in 2013 (previous guidance: double digit Non GAAP earnings growth).

Looking forward, we anticipate continuing operating leverage in 2014 and 2015, from reduced combined Non GAAP R&D and SG&A. We expect this to be around $250 million lower than current consensus in 2014 and $300 million lower than current consensus in 2015[2].

[1] Improvements of approximately $250 million for full year 2013, based on the difference between initial guidance for full year 2013 of high single digit growth in combined Non GAAP R&D and SG&A (guidance provided February 14, 2013) and current guidance expectations of combined Non GAAP R&D and SG&A to be 1-3% lower than 2012.

[2] Based on the most recent consensus estimates compiled by Consensus Forecast Ltd, as of the date of this release, of combined Non GAAP R&D and SG&A of $2,662 million and $2,683 million for the years ending December 31, 2014 and 2015 respectively, available on Shire's website (http://www.shire.com/shireplc/en/investors/forecasts).

THIRD QUARTER 2013 AND RECENT PIPELINE DEVELOPMENTS


Pipeline


ABH001 - for the treatment of Epidermolysis Bullosa

  •  This program has been discontinued as part of the prioritization of Shire's pipeline.

OTHER DEVELOPMENTS

Decision to discontinue the construction of the new manufacturing facility in San Diego


    '/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
11. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , Switzerland , ... Debiopharm International SA (Debiopharm), part of Debiopharm Group ™ , ... drugs that target unmet medical needs as ... preclinical data on the investigational compounds Debio 1143 ... will be presented at the 2015 Annual ...
(Date:4/16/2015)... 2015 Fairleigh Dickinson University ( ... to become the Executive Director of the Rothman ... the kick-off of the Initiative for Patient Centered ... Gulfo, under the Rothman Institute of Innovation and ... in collaboration with FDU’s School of Pharmacy’s Center ...
(Date:4/16/2015)... 2015 Dana-Farber Cancer Institute and ... Resolution Bioscience, Inc. today announced the successful completion ... blood-based, clinic ready, Next Generation Sequencing (NGS) assay ... is the first to demonstrate the successful sequencing ... in blinded plasma samples and highlights the ability ...
(Date:4/16/2015)... California (PRWEB) April 16, 2015 CCI ... incentives, MDF and joint planning management software for major ... its latest industry benchmark survey of channel vendor programs ... explores:, How the top IT ... now and through the coming year. , ...
Breaking Biology Technology:Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3CCI’s Channel Program Study Reveals 40% of IT Vendor Channel Staff Lack Adequate Access to Program and Partner Data 2CCI’s Channel Program Study Reveals 40% of IT Vendor Channel Staff Lack Adequate Access to Program and Partner Data 3
... Inc. (Microbia), an emerging leader in the production ... technology, has announced that Mike Doyle has joined ... manager of nutrition ingredients. Mike is the ... and will lead Microbia,s food ingredients business initiatives. ...
... HOUSTON, April 2 US Oncology , ... US Oncology Clinical Development (USOCD), a ... formalizes many of the services that US Oncology ... For more than a decade US Oncology Research has offered ...
... Intercell,s IXIARO, the first licensed vaccine against Japanese ... -- This final decision follows the positive opinion ... in December 2008VIENNA, April 2 Intercell AG ... to prevent Japanese Encephalitis, IXIARO(R), has been approved ...
Cached Biology Technology:Microbia, Inc. Names Mike Doyle as Senior Vice President and General Manager, Nutrition Ingredients 2Microbia, Inc. Names Mike Doyle as Senior Vice President and General Manager, Nutrition Ingredients 3US Oncology Provides Full Service Management of Clinical Trials 2US Oncology Provides Full Service Management of Clinical Trials 3Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis 2Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis 3Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis 4
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/9/2015)... JOSE, Calif. , April 9, 2015 ... human interface solutions, announced today that it will report ... on Thursday, April 23, 2015, after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... increasingly common sight at airports and on loading ... evaluate suspicious packages. A new test material developed ... (NIST) in cooperation with ASTM International enables users ... reliability. The new testing material, NIST Standard ...
... Researchers at Weill Cornell Medical College have shown that it ... their technique could possibly be used on other mammals -- ... species-non-specific and are similar in both females and males. For ... adverse effects of hormone administration. In the Feb. 24 ...
... and Forest Degradation ,Plus, (REDD+) is a climate ... landowners and stewards for "avoiding" forest loss and ... forest management and the enhancement of forest carbon ... the potential to generate a valuable stream of ...
Cached Biology News:NIST, ASTM land a one-two punch to fight explosives terrorism 2Immune therapy can control fertility in mammals 2REDD+, Technical, Socioeconomic and Political Dimensions 2REDD+, Technical, Socioeconomic and Political Dimensions 3
Homo sapiens inhibin, beta B (activin AB beta polypeptide) Antigen: Recombinant Protein(142~254aa)...
Self Closing Forceps...
Mouse IL-31 RA Biotinylated Affinity Purified PAb...
... 8 micro-bore tubes to 1 outflow ... tips, Rapid (several millisecond) solution change ... prevention , Solid construction 360, 250 ... For mounting on any micromanipulator Available ...
Biology Products: